Fourpath Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$530K |
| 2 |
FT Vest US Equity Buffer ETF July
FJUL
|
+$508K |
| 3 |
Gilead Sciences
GILD
|
+$351K |
| 4 |
Target
TGT
|
+$267K |
| 5 |
Eli Lilly
LLY
|
+$238K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ProShares Short Russell2000
RWM
|
+$3.92M |
| 2 |
ProShares Short High Yield
SJB
|
+$2.41M |
| 3 |
ProShares Short S&P500
SH
|
+$2.23M |
| 4 |
VanEck Gold Miners ETF
GDX
|
+$1.35M |
| 5 |
Medtronic
MDT
|
+$565K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 37.51% |
| 2 | Energy | 16.92% |
| 3 | Technology | 8.48% |
| 4 | Financials | 6.92% |
| 5 | Healthcare | 6.43% |
Similar funds
Fourpath Capital Management's Q1 2024 Portfolio in Review
As of Q1 2024, Fourpath Capital Management held 148 positions worth $144M, down 2% from $147M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Fourpath Capital Management withdrew a net $10.8M in Q1 2024, closing 8 positions and reducing 78 holdings. Its most notable exit was Medtronic, an estimated $565K position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 38% of assets, down from 43% a quarter earlier, followed by Energy and Technology.
Against the trend, Fourpath Capital Management opened a new position in Bristol-Myers Squibb worth $564K.
- Fourpath Capital Management's largest Q1 2024 buy was Bristol-Myers Squibb: 10,407 shares worth $564K.
- Fourpath Capital Management added most to Gilead Sciences in Q1 2024, an estimated $351K increase.
- Fourpath Capital Management's biggest Q1 2024 reduction was ProShares Short Russell2000, cutting an estimated $3.92M.
- Fourpath Capital Management fully exited Medtronic in Q1 2024, selling an estimated $565K.
- Fourpath Capital Management's ten largest holdings make up 48% of its $144M portfolio in Q1 2024.
- Fourpath Capital Management opened 12 new positions and closed 8 in Q1 2024.
- Fourpath Capital Management's portfolio value fell 2% quarter-over-quarter to $144M.
Based on Fourpath Capital Management's 13F filing for Q1 2024, filed 7 May 2024.